Key Highlights

Risk & Performance

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Phase 1

3(75.0%)

Phase 2

1(25.0%)

4Total

Phase 1(3)

Phase 2(1)

Loading network data...

Showing 5 of 5 trials

Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

Role: lead

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma

Role: lead

Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

Role: lead

Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients

Role: lead

Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants

Role: lead

All 5 trials loaded